Remarks

• See Section 6 regarding identifying patients at moderate risk of hospitalization.
• The GDG considered that nirmatrelvir-ritonavir represents a superior choice to molnupiravir because it probably has a greater reduction in hospitalization and because of concerns about possible harms of molnupiravir.
• In moderate risk patients for whom nirmatrelvir-ritonavir is not an option where a choice exists between molnupiravir and remdesivir, key considerations will be the potential toxicity of molnupiravir, its possible reduction in duration of symptoms, and the burden of remdesivir in requiring 3 days of intravenous injections.